Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 720

Similar articles for PubMed (Select 18180434)

1.

Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.

Bush G, Spencer TJ, Holmes J, Shin LM, Valera EM, Seidman LJ, Makris N, Surman C, Aleardi M, Mick E, Biederman J.

Arch Gen Psychiatry. 2008 Jan;65(1):102-14. doi: 10.1001/archgenpsychiatry.2007.16.

PMID:
18180434
2.

A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.

Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD.

J Clin Psychiatry. 2008 Jan;69(1):149-59. Erratum in: J Clin Psychiatry. 2008 Feb;69(2):329.

PMID:
18312050
3.

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.

Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.

Arch Pediatr Adolesc Med. 2006 Jan;160(1):82-90.

PMID:
16389216
4.

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.

J Clin Psychiatry. 2008 Dec;69(12):1938-47. Epub 2008 Dec 2.

PMID:
19192455
5.

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.

J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.

PMID:
19440077
6.

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G.

Pediatrics. 2001 Oct;108(4):883-92.

PMID:
11581440
7.
8.

Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study.

Bush G, Holmes J, Shin LM, Surman C, Makris N, Mick E, Seidman LJ, Biederman J.

Psychiatry Res. 2013 Jan 30;211(1):88-91. doi: 10.1016/j.pscychresns.2012.09.004. Epub 2012 Nov 10.

9.

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.

Biol Psychiatry. 2008 May 15;63(10):981-9. doi: 10.1016/j.biopsych.2007.11.008. Epub 2008 Jan 22.

PMID:
18206857
10.

The effects of stimulant medication on working memory functional connectivity in attention-deficit/hyperactivity disorder.

Wong CG, Stevens MC.

Biol Psychiatry. 2012 Mar 1;71(5):458-66. doi: 10.1016/j.biopsych.2011.11.011. Epub 2011 Dec 29.

11.

The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder.

Shafritz KM, Marchione KE, Gore JC, Shaywitz SE, Shaywitz BA.

Am J Psychiatry. 2004 Nov;161(11):1990-7.

PMID:
15514398
12.

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gómez N, Yelmo S, Ferrer M, Martínez Y, Casas M.

CNS Drugs. 2008;22(7):603-11.

PMID:
18547128
13.

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.

Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053.

PMID:
22945622
14.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

PMID:
19165529
16.

Effect of methylphenidate on auditory event related potential in boys with attention deficit hyperactivity disorder.

Ozdag MF, Yorbik O, Ulas UH, Hamamcioglu K, Vural O.

Int J Pediatr Otorhinolaryngol. 2004 Oct;68(10):1267-72.

PMID:
15364497
17.
18.

Shared and disorder-specific prefrontal abnormalities in boys with pure attention-deficit/hyperactivity disorder compared to boys with pure CD during interference inhibition and attention allocation.

Rubia K, Halari R, Smith AB, Mohammad M, Scott S, Brammer MJ.

J Child Psychol Psychiatry. 2009 Jun;50(6):669-78. doi: 10.1111/j.1469-7610.2008.02022.x. Epub 2009 Jan 5.

PMID:
19236528
20.

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.

Biol Psychiatry. 2006 May 1;59(9):829-35. Epub 2005 Dec 20. Erratum in: Biol Psychiatry. 2007 Jun 15;61(12):1402.

PMID:
16373066
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk